Strengths of this study were the prospective design, exclusion of NSCLC patients that were treated with potentially mutagenic chemotherapy or radiotherapy, a precise protocol for tumor regions sampling for genetic analysis and random selection of patients for comparison of KRAS mutation status in cancer tissue, blood and EBC–DNA. The gene discussed is KRAS; the disease is neoplasm.